Castleark Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $47.7M | Buy |
342,150
+64,822
| +23% | +$9.08M | 1.58% | 14 |
|
|
2025
Q4 | $34M | Buy |
277,328
+136,296
| +97% | +$16.6M | 1% | 21 |
|
|
2025
Q3 | $15.7M | Buy |
141,032
+135,700
| +2,545% | +$15.4M | 0.44% | 39 |
|
|
2025
Q2 | $591K | Hold |
5,332
| – | – | 0.02% | 224 |
|
|
2025
Q1 | $597K | Hold |
5,332
| – | – | 0.02% | 234 |
|
|
2024
Q4 | $493K | Hold |
5,332
| – | – | 0.02% | 234 |
|
|
2024
Q3 | $447K | Hold |
5,332
| – | – | 0.02% | 218 |
|
|
2024
Q2 | $366K | Hold |
5,332
| – | – | 0.01% | 229 |
|
|
2024
Q1 | $391K | Hold |
5,332
| – | – | 0.02% | 235 |
|
|
2023
Q4 | $432K | Hold |
5,332
| – | – | 0.02% | 236 |
|
|
2023
Q3 | $400K | Hold |
5,332
| – | – | 0.02% | 226 |
|
|
2023
Q2 | $411K | Hold |
5,332
| – | – | 0.02% | 224 |
|
|
2023
Q1 | $442K | Hold |
5,332
| – | – | 0.02% | 225 |
|
|
2022
Q4 | $458K | Hold |
5,332
| – | – | 0.02% | 237 |
|
|
2022
Q3 | $329K | Hold |
5,332
| – | – | 0.02% | 242 |
|
|
2022
Q2 | $330K | Sell |
5,332
-3,518
| -40% | -$218K | 0.02% | 240 |
|
|
2022
Q1 | $526K | Hold |
8,850
| – | – | 0.02% | 242 |
|
|
2021
Q4 | $643K | Hold |
8,850
| – | – | 0.02% | 254 |
|
|
2021
Q3 | $618K | Hold |
8,850
| – | – | 0.02% | 241 |
|
|
2021
Q2 | $609K | Hold |
8,850
| – | – | 0.02% | 242 |
|
|
2021
Q1 | $572K | Hold |
8,850
| – | – | 0.02% | 248 |
|
|
2020
Q4 | $516K | Hold |
8,850
| – | – | 0.02% | 279 |
|
|
2020
Q3 | $559K | Hold |
8,850
| – | – | 0.02% | 269 |
|
|
2020
Q2 | $681K | Hold |
8,850
| – | – | 0.03% | 232 |
|
|
2020
Q1 | $662K | Hold |
8,850
| – | – | 0.04% | 211 |
|
|
2019
Q4 | $575K | Hold |
8,850
| – | – | 0.02% | 274 |
|
|
2019
Q3 | $561K | Hold |
8,850
| – | – | 0.02% | 273 |
|
|
2019
Q2 | $598K | Hold |
8,850
| – | – | 0.02% | 279 |
|
|
2019
Q1 | $575K | Sell |
8,850
-89,018
| -91% | -$5.92M | 0.02% | 289 |
|
|
2018
Q4 | $6.12M | Sell |
97,868
-7,640
| -7% | -$534K | 0.26% | 123 |
|
|
2018
Q3 | $8.15M | Sell |
105,508
-1,000
| -0.9% | -$75.5K | 0.23% | 137 |
|
|
2018
Q2 | $7.54M | Sell |
106,508
-1,240
| -1% | -$87.6K | 0.23% | 138 |
|
|
2018
Q1 | $8.12M | Sell |
107,748
-5,330
| -5% | -$424K | 0.26% | 125 |
|
|
2017
Q4 | $8.1M | Sell |
113,078
-5,740
| -5% | -$436K | 0.24% | 135 |
|
|
2017
Q3 | $9.63M | Buy |
118,818
+109,968
| +1,243% | +$8.41M | 0.3% | 113 |
|
|
2017
Q2 | $626K | Sell |
8,850
-6,400
| -42% | -$426K | 0.02% | 300 |
|
|
2017
Q1 | $1.04M | Sell |
15,250
-2,400
| -14% | -$169K | 0.03% | 293 |
|
|
2016
Q4 | $1.26M | Sell |
17,650
-213,350
| -92% | -$15.9M | 0.04% | 285 |
|
|
2016
Q3 | $18.3M | Sell |
231,000
-81,130
| -26% | -$6.59M | 0.55% | 43 |
|
|
2016
Q2 | $26M | Sell |
312,130
-24,780
| -7% | -$2.2M | 0.83% | 35 |
|
|
2016
Q1 | $30.9M | Sell |
336,910
-36,160
| -10% | -$3.26M | 0.97% | 29 |
|
|
2015
Q4 | $37.8M | Sell |
373,070
-143,300
| -28% | -$14.9M | 1.13% | 26 |
|
|
2015
Q3 | $50.7M | Sell |
516,370
-20,400
| -4% | -$2.27M | 1.63% | 8 |
|
|
2015
Q2 | $62.8M | Sell |
536,770
-122,730
| -19% | -$13.4M | 1.68% | 7 |
|
|
2015
Q1 | $64.7M | Sell |
659,500
-97,220
| -13% | -$9.87M | 1.56% | 7 |
|
|
2014
Q4 | $71.3M | Sell |
756,720
-169,250
| -18% | -$17.5M | 1.84% | 8 |
|
|
2014
Q3 | $65.6M | Buy |
925,970
+500,410
| +118% | +$49M | 1.87% | 12 |
|
|
2014
Q2 | $35.3M | Sell |
425,560
-500,410
| -54% | -$39M | 0.97% | 33 |
|
|
2014
Q1 | $65.6M | Sell |
925,970
-480,811
| -34% | -$37.7M | 1.87% | 12 |
|
|
2013
Q4 | $106M | Buy |
1,406,781
+1,153,631
| +456% | +$80.3M | 3.07% | 1 |
|
|
2013
Q3 | $26.9M | Sell |
253,150
-887,850
| -78% | -$53.1M | 0.76% | 39 |
|
|
2013
Q2 | $58.5M | Buy |
+1,141,000
| New | +$59.5M | 1.94% | 19 |
|
Other funds holding GILD
VCM
VPM
Castleark Management's GILD Position: Q1 2026 in Review
Castleark Management increased its Gilead Sciences (GILD) stake by 23% in Q1 2026, buying an estimated $9.08M and bringing the position to 342,150 shares worth $47.7M. The position accounts for 1.58% of the portfolio, ranked #14.
Castleark Management first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $106M in Q4 2013. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Castleark Management held 342,150 shares of Gilead Sciences worth $47.7M as of Q1 2026.
- Castleark Management bought 64,822 Gilead Sciences shares in Q1 2026, an estimated $9.08M.
- Gilead Sciences made up 1.58% of Castleark Management's portfolio in Q1 2026, its #14 holding.
- Castleark Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
- Castleark Management's Gilead Sciences position peaked at $106M in Q4 2013.
- 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Castleark Management's 13F filing for Q1 2026, filed 15 May 2026.